Pharmaceutical News and Articles

Recommendations Developed for Primary Care Asthma Management in Veterans, Military Members

In a synopsis of a clinical practice guideline issued by the U.S. Department of Veterans Affairs and U.S. Department of Defense and published online Feb. 17 in

Couples Who Do This One Thing Feel More Satisfied And Secure Together

TUESDAY, Feb. 17, 2026 Couples who take time to slow down and enjoy the good moments they share may feel closer, argue less and feel more confident their relati

FDA Approves Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the Only EGFR-Targeted Therapy that can be Administered Once a Month

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma

Baxdrostat Demonstrated Statistically Significant and Clinically Meaningful Reduction in Systolic Blood Pressure in Patients with Hard-to-Control Hypertension in the BaxHTN Phase III Trial

Positive full results from the BaxHTN Phase III trial showed baxdrostat demonstrated a statistically significant and clinically meaningful reduction in mean sea

Greenwich LifeSciences’ GLSI-100 Granted US FDA Fast Track Designation

Greenwich LifeSciences, Inc. (Nasdaq GLSI) (the Company ), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, whic

U.S. FDA Approves Expanded Indication for Vonvendi [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease

FDA Approves Inlexzo (gemcitabine intravesical system) for the Treatment of Non-Muscle Invasive Bladder Cancer

FDA Approves Inlexzo (gemcitabine intravesical system) for the Treatment of Non-Muscle Invasive Bladder Cancer

FDA Files Corcept’s New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer

FDA Approves Selumetinib for Pediatric Patients 1 year of Age and Older with Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas

The FDA expanded Koselugo’s approval to include children as young as 1 year with NF1 and symptomatic, inoperable plexiform neurofibromas.